Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related BMY
Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate
Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More
Bristol-Myers Squibb's Empliciti reduced risk of cancer progression in mid-stage MM study (Seeking Alpha)
Related HOG
Auto Stock Roundup: GM, Honda, Tesla And More
A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings, Economic Data

Analysts at Barclays downgraded Bristol-Myers Squibb Company (NYSE: BMY) from “overweight” to “equal-weight.” The target price for Bristol-Myers Squibb has been lowered from $65 to $46. Bristol-Myers Squibb's shares closed at $48.12 yesterday.

Analysts at Raymond James downgraded Harley-Davidson (NYSE: HOG) from “strong buy” to “market perform” and removed the price target of $84. Harley-Davidson's shares closed at $70.33 yesterday.

Baird downgraded U.S. Bancorp (NYSE: USB) from “outperform” to “neutral.” The price target for U.S. Bancorp is set to $44. U.S. Bancorp's shares closed at $43.34 yesterday.

Credit Suisse downgraded Hormel Foods (NYSE: HRL) from “outperform” to “neutral.” Hormel's shares closed at $49.19 yesterday.

Latest Ratings for BMY

DateFirmActionFromTo
May 2018UBSDowngradesBuyNeutral
Apr 2018BarclaysMaintainsEqual-WeightEqual-Weight
Apr 2018BMO CapitalUpgradesUnderperformMarket Perform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (BMY + HOG)

View Comments and Join the Discussion!